{"id":67417,"date":"2026-06-20T16:40:50","date_gmt":"2026-06-20T11:10:50","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=67417"},"modified":"2026-06-20T16:40:53","modified_gmt":"2026-06-20T11:10:53","slug":"neurohumoral-activation-in-heart-failure","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/neurohumoral-activation-in-heart-failure\/","title":{"rendered":"Neurohumoral Activation in Heart Failure"},"content":{"rendered":"<iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/QoO-tbuUB7c?si=-Vh2c4XfIpwQazoc\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n\n<p class=\"wp-block-paragraph\">Neurohumoral activation in heart failure (HF) represents a classic physiological paradox: short-term evolutionary compensatory mechanisms\u2014designed to maintain blood pressure and vital organ perfusion during acute volume loss\u2014transform into the primary drivers of progressive, maladaptive disease.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">When cardiac output falls, arterial underfilling unloads high-pressure baroreceptors (in the carotid sinus and aortic arch) and renal mechanoreceptors. This triggers an immediate, relentless cascade across three primary neuroendocrine axes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The interplay between the central nervous system, failing myocardium, and circulating hormones creates a self-reinforcing loop of systemic vasoconstriction, volume retention, and direct tissue toxicity.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As the cardioregulatory center perceives diminished effective arterial blood volume, it drives sympathetic outflow and renin release, ultimately increasing cardiac workload and accelerating ventricular remodeling.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The Three Maladaptive Axes<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">1. The Sympathetic Nervous System (SNS)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Loss of inhibitory baroreceptor tone leads to a massive outflow of norepinephrine (NE) and epinephrine from sympathetic nerve terminals and the adrenal medulla.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Hemodynamic impact:<\/strong> Increases heart rate (chronotropy) and contractility (inotropy) while causing potent peripheral vasoconstriction, driving up left ventricular afterload.<\/li>\n\n\n\n<li class=\"\"><strong>Cellular toxicity:<\/strong> Chronic exposure to high circulating catecholamine levels induces myocyte apoptosis, triggers life-threatening ventricular arrhythmias, and causes a structural downregulation and uncoupling of myocardial \u03b2<sub>1<\/sub>-adrenergic receptors.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">2. The Renin-Angiotensin-Aldosterone System (RAAS)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Renal hypoperfusion, combined with direct \u03b2<sub>1<\/sub>-stimulation of the juxtaglomerular apparatus, prompts the continuous release of renin.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Angiotensin II:<\/strong> Acts as a potent systemic vasoconstrictor and directly stimulates myocardial and vascular hypertrophy. It also triggers the adrenal glands to release aldosterone and the posterior pituitary to secrete vasopressin.<\/li>\n\n\n\n<li class=\"\"><strong>Aldosterone:<\/strong> Beyond driving distal tubular sodium and water retention, aldosterone is a potent pro-fibrotic hormone. It stimulates fibroblast proliferation and collagen deposition within the myocardial interstitium, stiffening the ventricle and worsening diastolic compliance.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">3. Arginine Vasopressin (AVP)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Also known as antidiuretic hormone (ADH), AVP is released non-osmotically in response to perceived arterial underfilling.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\">By binding to <strong>V<sub>1\u03b1<\/sub> receptors<\/strong>, it contributes to systemic vasoconstriction and increases afterload.<\/li>\n\n\n\n<li class=\"\">By binding to <strong>V<sub>2<\/sub> receptors<\/strong> in the renal collecting ducts, it drives pure free-water reabsorption. This dilutes serum sodium, making dilutional hyponatremia a classic clinical hallmark of advanced, end-stage neurohumoral activation.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">The Overwhelmed Counter-Regulatory System<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">To counteract this profound vasoconstrictive and volume-retaining onslaught, the failing myocardium secretes <strong>Natriuretic Peptides (ANP and BNP)<\/strong> in response to increased wall stress and ventricular stretch.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The natriuretic peptide system attempts to promote vasodilation, natriuresis, and diuresis while directly inhibiting renin and aldosterone synthesis. However, in chronic HF, this favorable axis is completely overwhelmed by the sheer magnitude of RAAS\/SNS activation. Its efficacy is further blunted by target-receptor desensitization and rapid enzymatic degradation by circulating <strong>neprilysin<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Translation to Guideline-Directed Medical Therapy (GDMT)<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Modern pharmacological management of HFrEF is fundamentally an exercise in targeted neurohumoral blockade, shifting the therapeutic focus from simple hemodynamic support to interrupting these toxic cellular pathways:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Neurohumoral Axis<\/strong><\/td><td><strong>Primary Pathophysiological Harm<\/strong><\/td><td><strong>Targeted GDMT Class<\/strong><\/td><\/tr><\/thead><tbody><tr><td><strong>SNS<\/strong><\/td><td>Catecholamine toxicity, apoptosis, arrhythmogenesis<\/td><td><strong>Beta-Blockers<\/strong> (Carvedilol, Metoprolol succinate, Bisoprolol)<\/td><\/tr><tr><td><strong>RAAS (Ang II)<\/strong><\/td><td>Vasoconstriction, afterload mismatch, myocyte hypertrophy<\/td><td><strong>ACEi \/ ARB<\/strong><\/td><\/tr><tr><td><strong>RAAS (Aldosterone)<\/strong><\/td><td>Interstitial cardiac fibrosis, potassium wasting, volume retention<\/td><td><strong>MRAs<\/strong> (Spironolactone, Eplerenone)<\/td><\/tr><tr><td><strong>Natriuretic Peptides<\/strong><\/td><td>Favorable counter-regulatory system blunted by enzymatic breakdown<\/td><td><strong>ARNI<\/strong> (Sacubitril component inhibits neprilysin)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">By deploying an ARNI alongside a beta-blocker and an MRA, foundational therapy simultaneously severs the toxic RAAS\/SNS feedback loops while artificially preserving and amplifying the heart&#8217;s endogenous protective mechanisms.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Molecular pathways of <strong>\u03b2<sub>1<\/sub><\/strong> adrenergic receptor downregulation and desensitization in chronic heart failure<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">In chronic heart failure with reduced ejection fraction (HFrEF), the continuous flood of synaptic and circulating catecholamines forces sarcolemmal <strong>\u03b2<sub>1<\/sub>-adrenergic receptors <\/strong>into a state of relentless occupancy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Rather than allowing this hyperadrenergic state to drive unchecked calcium entry\u2014which would trigger fatal myocyte hypercontraction, energy depletion, and necrosis\u2014the myocyte initiates a self-protective, multi-tiered dampening cascade.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This process occurs across a strict chronological continuum: <strong>uncoupling<\/strong> (seconds to minutes), <strong>internalization<\/strong> (minutes to hours), and <strong>absolute downregulation<\/strong> (hours to days).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">1. Receptor Uncoupling: Functional Desensitization<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><em>(Timeframe: Seconds to Minutes)<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The earliest phase of desensitization blunts the receptor&#8217;s ability to transmit a signal without actually removing the receptor from the cell membrane.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>GRK2 Upregulation:<\/strong> The primary molecular driver is <strong>G-protein coupled receptor kinase 2<\/strong> (GRK2, historically known as \u03b2-ARK1). In failing myocardium, chronic sympathetic tone drives a massive cytosolic upregulation of GRK2.<\/li>\n\n\n\n<li class=\"\"><strong>Receptor Phosphorylation:<\/strong> When norepinephrine binds the \u03b2<sub>1<\/sub> -AR, the receptor undergoes a conformational change that exposes its intracellular carboxyl-terminal tail and third intracellular loop. Cytosolic GRK2 identifies these active conformations and rapidly phosphorylates specific serine and threonine residues on these intracellular domains.<\/li>\n\n\n\n<li class=\"\"><strong>\u03b2-Arrestin Recruitment:<\/strong> The newly attached phosphate groups act as a high-affinity molecular beacon, drawing cytosolic <strong><strong>\u03b2<\/strong>-arrestin 1 and <strong>\u03b2<\/strong>-arrestin 2<\/strong> to the membrane.<\/li>\n\n\n\n<li class=\"\"><strong>Steric Hindrance:<\/strong> \u03b2-arrestin binds directly over the intracellular loops of the receptor. This creates a physical shield that blocks the receptor from interacting with its stimulatory G-protein (G<sub>s<\/sub>). The <strong>G<sub>s<\/sub> \u2192<\/strong> <strong>Adenylyl Cyclase (AC) \u2192<\/strong> <strong>cAMP \u2192<\/strong> <strong>PKA<\/strong> (Protein Kinase A) axis is instantly severed, dropping intracellular calcium transients even though the receptor remains fully exposed to extracellular catecholamines.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">2. Endosomal Sequestration: Internalization<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><em>(Timeframe: Minutes to Hours)<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Once bound to the uncoupled receptor, \u03b2-arrestin shifts from a physical blocker to a structural adaptor protein, initiating the physical clearance of the receptor from the sarcolemma.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Clathrin Lattice Formation:<\/strong> \u03b2-arrestin undergoes a conformational shift that exposes binding sites for <strong>clathrin<\/strong> and the clathrin adaptor protein 2 (<strong>AP-2<\/strong>) complex.<\/li>\n\n\n\n<li class=\"\"><strong>Vesicular Invagination:<\/strong> The AP-2 complex gathers the uncoupled, \u03b2-arrestin-bound \u03b2<sub>1<\/sub>-ARs and clusters them into clathrin-coated pits on the myocyte surface.<\/li>\n\n\n\n<li class=\"\"><strong>Dynamin Scission:<\/strong> The large GTPase (Guanosine Triphosphatase) enzyme <strong>dynamin<\/strong> wraps around the neck of the invaginated pit, constricts, and pinches it off, pulling the \u03b2<sub>1<\/sub>-AR inside the cell into an intracellular early endosome.<\/li>\n\n\n\n<li class=\"\"><strong>The &#8220;Fate Fork&#8221;:<\/strong> Inside the endosome, the receptor faces a critical sorting decision:\n<ol start=\"1\" class=\"wp-block-list\">\n<li class=\"\"><em>Resensitization:<\/em> If the catecholamine stimulus drops, intra-endosomal phosphatases strip the phosphate groups, \u03b2-arrestin dissociates, and the receptor is recycled back to the sarcolemma.<\/li>\n\n\n\n<li class=\"\"><em>Degradation:<\/em> In chronic HF, the unrelenting catecholamine presence forbids recycling, forcing the endosome down the degradative pathway.<\/li>\n<\/ol>\n<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">3. Absolute Downregulation: Degradation &amp; Gene Suppression<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><em>(Timeframe: Hours to Days)<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Because the hyperadrenergic state of HF does not abate, the internalized receptors are permanently purged from the myocyte&#8217;s total protein pool.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Lysosomal Destruction:<\/strong> The early endosomes containing sequestered \u03b2<sub>1<\/sub>-ARs are matured into late endosomes and trafficked to <strong>lysosomes<\/strong>. The vesicles fuse, and intra-lysosomal proteolytic enzymes completely degrade the receptor proteins.<\/li>\n\n\n\n<li class=\"\"><strong>Transcriptional Suppression:<\/strong> Simultaneously, the prolonged activation of downstream transcription factors\u2014specifically the <strong>Inducible cAMP Early Repressor (ICER)<\/strong>\u2014binds to the promoter region of the <em>ADRB1<\/em> (Adrenoceptor Beta 1) gene, actively halting the synthesis of new \u03b2<sub>1<\/sub>-AR mRNA.<\/li>\n\n\n\n<li class=\"\"><strong>mRNA Destabilization:<\/strong> Post-transcriptionally, specific cytosolic RNA-binding proteins bind to the remaining <em>ADRB1<\/em> mRNA transcripts, accelerating their enzymatic decay before they can reach the ribosomes.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">The Shifting Sarcolemmal Ratio<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In a healthy left ventricle, the ratio of \u03b2<sub>1<\/sub> to \u03b2<sub>2<\/sub> receptors is roughly <strong>80:20<\/strong>. Because \u03b2<sub>2<\/sub>-ARs do not undergo the same aggressive GRK2-mediated internal destruction, chronic HF results in a selective loss of up to <strong>50% to 60% of absolute \u03b2<sub>1<\/sub> density<\/strong>. Consequently, the failing sarcolemma shifts to a severely blunted ratio of roughly <strong>60:40<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">4. Post-Receptor Collapse: The G<sub>s<\/sub>-to-G<sub>i<\/sub> Shift<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The physical loss of \u03b2<sub>1<\/sub>-receptors is compounded by a profound pathological restructuring of the surviving downstream machinery:<\/p>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li class=\"\"><strong>Upregulation of G<sub>i<\/sub>:<\/strong> Failing myocytes explicitly upregulate the expression of inhibitory G-proteins (G<sub>i<\/sub>).<\/li>\n\n\n\n<li class=\"\"><strong>Protein Kinase A<\/strong> (<strong>PKA<\/strong>) <strong>Class-Switching:<\/strong> Persistent low-level PKA activity in the failing heart phosphorylates the intracellular domains of the <em>surviving<\/em> \u03b2<sub>2<\/sub>-receptors. This specific phosphorylation alters the receptor&#8217;s affinity, forcing it to uncouple from stimulatory G<sub>s<\/sub> and couple directly to <strong>G<sub>i<\/sub><\/strong>.<\/li>\n\n\n\n<li class=\"\"><strong>Active Suppression:<\/strong> When circulating catecholamines bind these altered \u03b22-receptors, they now send an active <em>inhibitory<\/em> signal to adenylyl cyclase, throwing the molecular brakes on cAMP production.<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">Downstream Functional Consequence<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Without adequate cAMP to activate Protein Kinase A, the myocyte fails to phosphorylate <strong>Phospholamban (PLN)<\/strong>. Unphosphorylated PLN remains tightly bound to the <strong>SERCA2a<\/strong> pump, actively choking off the re-uptake of calcium into the sarcoplasmic reticulum.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The sarcoplasmic reticulum becomes severely depleted of calcium: systole fails because there is no calcium to release, and diastole fails because lingering cytosolic calcium prevents the myofibrils from relaxing.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">The &#8220;Beta-Blocker Paradox&#8221; Explained<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Understanding this precise molecular decay explains why <strong>Beta-Blockers<\/strong> (Carvedilol, Metoprolol succinate, Bisoprolol) serve as the cornerstone of HFrEF survival.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">By acting as competitive antagonists, beta-blockers sit in the sarcolemmal binding pocket and shield the receptor from circulating catecholamines. This abruptly starves GRK2 of its target, halts \u03b2-arrestin recruitment, stops clathrin-mediated endocytosis, and drops intracellular ICER levels. Given weeks of pharmacological shielding, the myocyte resumes <em>ADRB1<\/em> transcription, <strong>resensitizing and upregulating<\/strong> functional \u03b2<sub>1<\/sub>-receptors back to the cell surface.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Neurohumoral activation in heart failure (HF) represents a classic physiological paradox: short-term evolutionary compensatory mechanisms\u2014designed to maintain blood pressure and vital organ perfusion during acute volume loss\u2014transform into the primary drivers of progressive, maladaptive disease. When cardiac output falls, arterial underfilling unloads high-pressure baroreceptors (in the carotid sinus and aortic arch) and renal mechanoreceptors. This [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":67438,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-67417","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neurohumoral Activation in Heart Failure - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/neurohumoral-activation-in-heart-failure\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neurohumoral Activation in Heart Failure - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"Neurohumoral activation in heart failure (HF) represents a classic physiological paradox: short-term evolutionary compensatory mechanisms\u2014designed to maintain blood pressure and vital organ perfusion during acute volume loss\u2014transform into the primary drivers of progressive, maladaptive disease. When cardiac output falls, arterial underfilling unloads high-pressure baroreceptors (in the carotid sinus and aortic arch) and renal mechanoreceptors. This [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/neurohumoral-activation-in-heart-failure\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-20T11:10:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-20T11:10:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/06\/Neurohumoral-Activation-in-Heart-Failure.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1279\" \/>\n\t<meta property=\"og:image:height\" content=\"722\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/neurohumoral-activation-in-heart-failure\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/neurohumoral-activation-in-heart-failure\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Neurohumoral Activation in Heart Failure\",\"datePublished\":\"2026-06-20T11:10:50+00:00\",\"dateModified\":\"2026-06-20T11:10:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/neurohumoral-activation-in-heart-failure\\\/\"},\"wordCount\":1400,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/neurohumoral-activation-in-heart-failure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Neurohumoral-Activation-in-Heart-Failure.jpg\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/neurohumoral-activation-in-heart-failure\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/neurohumoral-activation-in-heart-failure\\\/\",\"name\":\"Neurohumoral Activation in Heart Failure - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/neurohumoral-activation-in-heart-failure\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/neurohumoral-activation-in-heart-failure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Neurohumoral-Activation-in-Heart-Failure.jpg\",\"datePublished\":\"2026-06-20T11:10:50+00:00\",\"dateModified\":\"2026-06-20T11:10:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/neurohumoral-activation-in-heart-failure\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/neurohumoral-activation-in-heart-failure\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/neurohumoral-activation-in-heart-failure\\\/#primaryimage\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Neurohumoral-Activation-in-Heart-Failure.jpg\",\"contentUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Neurohumoral-Activation-in-Heart-Failure.jpg\",\"width\":1279,\"height\":722},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/neurohumoral-activation-in-heart-failure\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neurohumoral Activation in Heart Failure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neurohumoral Activation in Heart Failure - All About Cardiovascular System and Disorders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/neurohumoral-activation-in-heart-failure\/","og_locale":"en_US","og_type":"article","og_title":"Neurohumoral Activation in Heart Failure - All About Cardiovascular System and Disorders","og_description":"Neurohumoral activation in heart failure (HF) represents a classic physiological paradox: short-term evolutionary compensatory mechanisms\u2014designed to maintain blood pressure and vital organ perfusion during acute volume loss\u2014transform into the primary drivers of progressive, maladaptive disease. When cardiac output falls, arterial underfilling unloads high-pressure baroreceptors (in the carotid sinus and aortic arch) and renal mechanoreceptors. This [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/professional\/neurohumoral-activation-in-heart-failure\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2026-06-20T11:10:50+00:00","article_modified_time":"2026-06-20T11:10:53+00:00","og_image":[{"width":1279,"height":722,"url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/06\/Neurohumoral-Activation-in-Heart-Failure.jpg","type":"image\/jpeg"}],"author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/neurohumoral-activation-in-heart-failure\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/neurohumoral-activation-in-heart-failure\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Neurohumoral Activation in Heart Failure","datePublished":"2026-06-20T11:10:50+00:00","dateModified":"2026-06-20T11:10:53+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/neurohumoral-activation-in-heart-failure\/"},"wordCount":1400,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/neurohumoral-activation-in-heart-failure\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/06\/Neurohumoral-Activation-in-Heart-Failure.jpg","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/neurohumoral-activation-in-heart-failure\/","url":"https:\/\/johnsonfrancis.org\/professional\/neurohumoral-activation-in-heart-failure\/","name":"Neurohumoral Activation in Heart Failure - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/neurohumoral-activation-in-heart-failure\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/neurohumoral-activation-in-heart-failure\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/06\/Neurohumoral-Activation-in-Heart-Failure.jpg","datePublished":"2026-06-20T11:10:50+00:00","dateModified":"2026-06-20T11:10:53+00:00","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/neurohumoral-activation-in-heart-failure\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/neurohumoral-activation-in-heart-failure\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/neurohumoral-activation-in-heart-failure\/#primaryimage","url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/06\/Neurohumoral-Activation-in-Heart-Failure.jpg","contentUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/06\/Neurohumoral-Activation-in-Heart-Failure.jpg","width":1279,"height":722},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/neurohumoral-activation-in-heart-failure\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Neurohumoral Activation in Heart Failure"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/67417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=67417"}],"version-history":[{"count":5,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/67417\/revisions"}],"predecessor-version":[{"id":67439,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/67417\/revisions\/67439"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media\/67438"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=67417"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=67417"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=67417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}